Oslo, 28th of March 2025: Reference is made to the stock exchange announcement
made by Medistim ASA on 11 March 2025 of the launch of Medistim's program to
repurchase up to 70,000 of the Company's shares in open market transactions for
a total amount of up to NOK 35,000,000 during the period from 11 March 2025,
until no later than 7 May 2025, pursuant to an agreement with DNB Markets. For
the period from and including 11 March 2025, through 28th of March 2025, the
Company purchased a total of 42,543 shares at an average price of NOK 186.1431
per share, all purchased as ordinary market purchases on Euronext Oslo Børs.
Please find below the transaction overview: 

-----------------------------------------------------------------------------

Date / Aggregated daily volume (#shares) / Weighted average share price per day
(NOK) / Total daily transaction value (NOK)		

Date: 24 mars 2025. Number of share: 3,000.  Avg price: NOK 186.6598 per share
Date: 25 mars 2025. Number of share: 3,000.  Avg price: NOK 186.7532 per share
Date: 26 mars 2025. Number of share: 3,000.  Avg price: NOK 183.0003 per share
Date: 27 mars 2025. Number of share: 3,000.  Avg price: NOK 179.2613 per share
Date: 28 mars 2025. Number of share: 3,000.  Avg price: NOK 178.4685 per share


Total for this period:
15,000 shares purchased at average share price of NOK 182.8290 per share. Total
transaction value was NOK 2,742,435.30.


Previously disclosed buybacks under the program:
27,543 shares purchased at average share price of NOK 187.9309 per share. Total
transaction value was NOK 5,176,183.41

-----------------------------------------------------------------------------

The issuer's holding of own shares: 
Following the completion of the above transactions, Medistim owns a total of
65,660 of own shares (including 23,117 shares owned prior to the launch of the
buyback program), corresponding to 0.358 % of Medistim's share capital. 

Appendix: 
An overview of all transactions made under the buyback program that have been
carried out during the above-mentioned time period is attached to this report
and available at www.newsweb.no.

For further information, please contact: 

Thomas Jakobsen, Chief Financial Officer, phone: +47 906 59 940
Mail: Thomas.jakobsen@medistim.com

This is information that Medistim is obliged to make public pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
Section 5-12 of the Norwegian Securities Trading Act.